Abstract
Metabolically active, genetically attenuated Plasmodium falciparum parasite lines are promising second-generation malaria vaccine candidates. Lamers et al. and Roozen et al. demonstrated in recent Phase 1/2a trials that GA2 parasites, designed to arrest late during liver-stage development and transmitted via mosquito bites, can induce substantial protection against sporozoite challenge infection.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call